A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

A Phase III, Open-Label, Randomized Study of On-Demand TACE Combined With Atezolizumab Plus Bevacizumab (Atezo/Bev) or On-Demand TACE Alone in Patients With Untreated Heaptocellular Carcionma

This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab combined with on-demand TACE compared to on-demand TACE alone in participants with hepatocellular carcinoma who are at high risk of poorer outcome following TACE treatment.

Inclusion Criteria:

• Confirmed diagnosis of HCC by histology/ cytology or clinical criteria
• Eligible for TACE treatment
• No prior systemic therapy for HCC, especially immunotherapy
• No prior locoregional therapy to the target lesion(s)
• At least one measurable untreated lesion
• ECOG Performance Status of 0-1
• Child-Pugh class A

Exclusion Criteria:

• Evidence of Vp3/4 and hepatic vein tumor thrombus (HVTT)
• Evidence of extrahepatic spread (EHS)
• Being a candidate for curative treatments
• Any condition representing a contraindication to TACE as determined by the investigators
• Active or history of autoimmune disease or immune deficiency
• Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding
• A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment
• Evidence of bleeding diathesis or significant coagulopathy